SCHEMBL20523142

SCHEMBL20523142

O=S1(=O)CCNCCS(=O)(=O)C1

nearest known ligand 0.31

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.31
MAPT P10636 1/20 0.31
PDE4A P27815 1/20 0.31
KDR P35968 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13422 0.86
Methane SCHEMBL28109159 0.83
Water SCHEMBL28235026 0.83
Piperazine SCHEMBL7529697 0.83 HIF1A (0.43) HIF1AMAPTPDE4AKDR
Hydrochloric Acid SCHEMBL1002624 0.83
Hydrochloric Acid SCHEMBL4261800 0.83 HIF1A (0.33) HIF1AMAPTPDE4AKDR
SCHEMBL2621589 0.75
SCHEMBL1869472 0.73
SCHEMBL345879 0.73
Hydrochloric Acid SCHEMBL18817103 0.73 CXCR4 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12012467-B2 Small molecule DCN1 inhibitors and therapeutic methods using the same REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-06-18 US disclosed
EP-3609876-B1 COVALENT SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME UNIV MICHIGAN REGENTS (US) 2022-03-30 EP disclosed
US-20200109167-A1 SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME UNIV MICHIGAN REGENTS (US) 2020-04-09 US disclosed
EP-3601245-A1 SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME The Regents of The University of Michigan (US) 2020-02-05 EP disclosed
US-20180289677-A1 Covalent Small Molecule DCN1 Inhibitors and Therapeutic Methods Using the Same THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2018-10-11 US disclosed
WO-2018183411-A1 SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2018-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180289677-A1 Covalent Small Molecule DCN1 Inhibitors and Therapeutic Methods Using the Same CAPNS1, DCLRE1A, DCUN1D2 HIF1A 3900/4885MAPT 618/4885PDE4A 1757/4885
US-20200109167-A1 SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME DCUN1D2, CLN6, CAPNS1 HIF1A 2744/4885MAPT 572/4885PDE4A 1187/4885
US-12012467-B2 Small molecule DCN1 inhibitors and therapeutic methods using the same DCUN1D2, CLN6, CAPNS1 HIF1A 2744/4885MAPT 572/4885PDE4A 1187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.